Back to Cell Types

NCI-H650Homo sapiens (Human)Cancer cell line

Also known as: NCIH650, H-650, H650

🤖 AI SummaryBased on 10 publications

Quick Overview

Human lung cancer cell line with known RB pathway alterations

Detailed Summary

NCI-H650 is a human lung cancer cell line derived from a non-small cell lung cancer (NSCLC) patient. This cell line exhibits specific genetic alterations in the RB pathway, including mutations in the RB1 gene. The RB pathway is a critical tumor suppressor pathway involved in cell cycle regulation and is frequently altered in various cancers. NCI-H650 has been used in studies investigating the role of RB pathway mutations in cancer progression and therapeutic response. Research on this cell line has contributed to understanding the molecular mechanisms underlying lung cancer development and has been utilized in drug screening assays to identify potential therapeutic targets.

Research Applications

RB pathway analysisCancer progression studiesDrug screening assays

Key Characteristics

RB1 mutationsNSCLC originUsed in tumor suppressor pathway research

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1575
Species	Homo sapiens (Human)
Tissue Source	Lung[UBERON:UBERON_0002048]

Donor Information

Age Category	Unknown
Sex	Male

Disease Information

Disease	Lung adenocarcinoma
Lineage	Lung
Subtype	Lung Adenocarcinoma
OncoTree Code	LUAD

DepMap Information

Source Type	ATCC
Source ID	ACH-000945_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Lys164Asn (c.492G>T)	Homozygous	-	from parent cell line NCI-H650
MutationSimple	KRAS	p.Gln61Leu (c.182A>T)	Heterozygous	-	PubMed=28683746, PubMed=24755471, PubMed=20570890, PubMed=12068308
MutationSimple	KIT	p.Glu306Ter (c.916G>T)	Heterozygous	-	from parent cell line NCI-H650
MutationSimple	KIT	p.Pro41Glnfs*6 (c.121delC)	Heterozygous	-	from parent cell line NCI-H650
MutationSimple	BRCA2	p.Ser871Ter (c.2612C>A)	Heterozygous	-	from parent cell line NCI-H650

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

10

D13S317

8,12

D16S539

8,11

D18S51

14,20

D19S433

13

D21S11

31

D2S1338

18,24

D3S1358

17

D5S818

11

D7S820

10,11

D8S1179

12,14

FGA

20,22

Penta D

12

Penta E

12

TH01

6,9.3

TPOX

8,11

vWA

17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources